Factors Influencing the Outcome of Patients with Primary Ewing Sarcoma of the Sacrum

Author:

Rechl Victor1ORCID,Ranft Andreas12ORCID,Bhadri Vivek34ORCID,Brichard Benedicte5ORCID,Collaud Stephane6ORCID,Cyprova Sona7ORCID,Eich Hans8,Ek Torben9ORCID,Gelderblom Hans10ORCID,Hardes Jendrik211ORCID,Haveman Lianne M.12ORCID,Hartmann Wolfgang13ORCID,Hauser Peter14ORCID,Heesen Philip1ORCID,Jürgens Heribert15,Kanerva Jukka16ORCID,Kühne Thomas17ORCID,Raciborska Anna18ORCID,Rascon Jelena1920ORCID,Streitbürger Arne211ORCID,Uhlenbruch Yasmin21,Timmermann Beate222ORCID,Kersting Josephine12ORCID,Pham Minh Thanh1,Dirksen Uta12ORCID

Affiliation:

1. Pediatrics III, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

2. German Cancer Consortium, Partnersite, Essen, Germany

3. Chris O’Brien Lifehouse, Camperdown, Australia

4. Faculty of Medicine and Health, University of Sydney, Camperdown, Australia

5. Cliniques Universitaires Saint Luc, Department of Pediatric Hematology and Oncology, Université Catholique de Louvain, Brussels, Belgium

6. Lung Clinic, Department of Thoracic Surgery, Cologne Merheim Hospital, University of Witten/Herdecke, Witten, Germany

7. Charles University, Motol Child Ren’s Hospital, Prague, Czech Republic

8. Radiotherapy and Radiooncology, University Hospital Muenster, West German Cancer Center Network, Muenster, Germany

9. Childhood Cancer Center Queen Silvia Children’s Hospital, Gothenburg, Sweden

10. Leiden University Medical Center, Department of Medical Oncology, Leiden, NL, USA

11. Clinic of Tumororthopedics, University Hospital Essen, West German Cancer Centre, Essen, Germany

12. Princess Máxima Center for Pediatric Oncology, Department of Solid Tumors, Utrecht, Netherlands

13. Gerhard Domagk Institute for Pathology, University Hospital Muenster, West German Cancer Center Network, Muenster, Germany

14. Velkey László Child’s, Health Center, Borsod-Abaúj-Zemplén County University Teaching Hospital, Miskolc, Hungary

15. Department of Pediatric Hematology and Oncology, University Children’s Hospital Münster, West German Cancer Center Network, Münster, Germany

16. HUS Helsinki University Hospital, New Children’s Hospital, Div. Hematology and Stem Cell Transplantation, Helsinki, Finland

17. Department of Oncology/Hematology, University Children’s Hospital Basel, Basel, Switzerland

18. Mother and Child Institute, Department of Oncology and Surgical Oncology for Children and Youth, Warsaw, Poland

19. Center for Pediatric Oncology and Hematology, Vilnius University Hospital Santaros Klinikos, Vilnius University, Vilnius, Lithuania

20. Clinics of Children’s Diseases, Faculty of Medicine, Vilnius University, Vilnius, Lithuania

21. Patient Representative, St. Josef’s Hospital Bochum, University Hospital, Bochum, Germany

22. Clinic for Particle Therapy, West German Proton Beam Centre, University Hospital Essen, West German Cancer Centre, German Cancer Research Centre (DKTK), Essen, Germany

Abstract

Background. Ewing sarcoma (EwS) is a rare and highly malignant bone tumor primarily affecting children, adolescents, and young adults. The pelvis, trunk, and lower extremities are the most common sites, while EwS of the sacrum as a primary site is very rare, and only few studies focusing on this location are published. Due to the anatomical condition, local treatment is challenging in sacral malignancies. We analyzed factors that might influence the outcome of patients suffering from sacral EwS. Methods. We retrospectively analyzed data of the GPOH EURO-E.W.I.N.G 99 trial and the EWING 2008 trial, with a cohort of 124 patients with localized or metastatic sacral EwS. The study endpoints were overall survival (OS) and event-free survival (EFS). OS and EFS were calculated using the Kaplan–Meier method, and univariate comparisons were estimated using the log-rank test. Hazard ratios (HRs) with respective 95% confidence intervals (CIs) were estimated in a multivariable Cox regression model. Results. The presence of metastases (3y-EFS: 0.33 vs. 0.68; P<0.001; HR = 3.4, 95% CI 1.7 to 6.6; 3y-OS: 0.48 vs. 0.85; P<0.001; HR = 4.23, 95% CI 1.8 to 9.7), large tumor volume (≥200 ml) (3y-EFS: 0.36 vs. 0.69; P=0.02; HR = 2.1, 95% CI 1.1 to 4.0; 3y-OS: 0.42 vs. 0.73; P=0.04; HR = 2.1, 95% CI 1.03 to 4.5), and age ≥18 years (3y-EFS: 0.41 vs. 0.60; P=0.02; HR = 2.6, 95% CI 1.3 to 5.2; 3y-OS: 0.294 vs. 0.59; P=0.01; HR = 2.92, 95% CI 1.29 to 6.6) were revealed as adverse prognostic factors. Conclusion. Young age seems to positively influence patients` survival, especially in patients with primary metastatic disease. In this context, our results support other studies, stating that older age has a negative impact on survival. Tumor volume, metastases, and the type of local therapy modality have an impact on the outcome of sacral EwS. Level of evidence: Level 2. This trial is registered with NCT00020566 and NCT00987636.

Funder

Projekt DEAL

Publisher

Hindawi Limited

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Oncology;Bone & Joint 360;2024-08-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3